1. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
- Author
-
Jérôme Vialaret, Aurore Jaffuel, Christophe Hirtz, Angelo Paci, Sylvain Lehmann, Laurent Pelletier, Sophie Broutin, Sophie Santelé, Alan Barnes, Laurent Tiers, Célia Pugnier, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pharmacologie, Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Plateforme de Protéomique Clinique, CHU Saint-Eloi, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHU Montpellier, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Oncology ,medicine.medical_specialty ,Bevacizumab ,medicine.drug_class ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Enzyme-Linked Immunosorbent Assay ,Monoclonal antibody ,030226 pharmacology & pharmacy ,01 natural sciences ,Mass Spectrometry ,Analytical Chemistry ,03 medical and health sciences ,0302 clinical medicine ,Limit of Detection ,Internal medicine ,medicine ,Humans ,Sample preparation ,Amino Acid Sequence ,General Pharmacology, Toxicology and Pharmaceutics ,Staphylococcal Protein A ,ComputingMilieux_MISCELLANEOUS ,medicine.diagnostic_test ,business.industry ,010401 analytical chemistry ,Cancer ,Analytic Sample Preparation Methods ,Antibodies, Monoclonal ,General Medicine ,medicine.disease ,0104 chemical sciences ,3. Good health ,Medical Laboratory Technology ,Workflow ,Therapeutic drug monitoring ,Proteolysis ,business ,medicine.drug ,Chromatography, Liquid - Abstract
Aim: Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies. Materials & methods: In this work, we developed a workflow based on an automated protein-A capture and LC–MS/MS analysis to quantify bevacizumab on patient serum during treatment. This analytical approach was fully validated and compared with a commercially available Monoclonal antibody-based treatment preparation (nanosurface and molecular-orientation limited kit). Results: The analytical comparison of the two preparative workflows based on protein-A capture gave similar results with a better lower limit of quantification for the nanosurface and molecular-orientation limited kit (0.26986 vs 1.9565 μg/ml). Conclusion: LC–MS/MS has clear advantages compared with ELISA when considering method development time, multiplexing capacities and absolute quantification with internal standardization.
- Published
- 2018
- Full Text
- View/download PDF